arrow
B

Bernd Jahrsdörfer

ulm university
H指数:36
被引数:8,117

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

SARS-CoV-2 convalescent plasma for the controlled clinical trial COVIC-19: Experience from collection of very high-titer plasma from superimmunized individuals

SARS-CoV-2康复期血浆用于COVIC-19控制临床试验:从超免疫个体中采集高滴度血浆的经验

2025-09-010
OAAI
Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease (vol 21, 837, 2023)
2024-06-130
OAAI
Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease
2023-11-212
OAAI
SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays

疗养员的SARS-CoV-2疫苗接种可增强对Omicron亚变体BA.1,BA.2和BA.5的中和能力,并且可以通过血清学检测中的抗S抗体浓度来预测

2023-04-253
OAAI
One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients
2022-12-1514
OAAI
High antibody levels and reduced cellular response in children up to one year after SARS-CoV-2 infection

SARS-CoV-2感染后长达一年的儿童抗体水平高和细胞反应降低

2022-11-2813
OAAI
Cytokine levels associated with favorable clinical outcome in the CAPSID randomized trial of convalescent plasma in patients with severe COVID-19
2022-10-062
OAAI
Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients
2022-05-0966
OAAI
B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab

B细胞数量可预测利妥昔单抗治疗患者SARS-CoV-2疫苗接种后的体液和细胞反应

2022-04-1748
OA
Robust and durable serological response following pediatric SARS-CoV-2 infection

小儿SARS-CoV-2感染后稳健持久的血清学反应

2022-01-1055
OAAI
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants
2022-01-0177
OAAI